Last reviewed · How we verify
JS201
At a glance
| Generic name | JS201 |
|---|---|
| Sponsor | Shanghai Junshi Bioscience Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer (PHASE2)
- Clinical Study of JS201 in Patients With Advanced Malignant Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JS201 CI brief — competitive landscape report
- JS201 updates RSS · CI watch RSS
- Shanghai Junshi Bioscience Co., Ltd. portfolio CI